Thorac Cancer: Retrospective analysis of the efficacy of docetaxel combined with ramucirumab in second-line treatment of advanced NSCLC patients with advanced chemotherapy combined with immunotherapy

Chemotherapy combined with immunotherapy has become the standard treatment option for patients with untreated advanced non-small cell lung cancer ( NSCLC )
.
However, many patients with advanced NSCLC develop disease progression after treatment

.

Chemotherapy combined with immunotherapy has become the standard treatment option for patients with untreated advanced non-small cell lung cancer ( NSCLC )

The study included 88 patients with advanced NSCLC who received chemotherapy combined with immunotherapy in 6 different institutions

.

The study included 88 patients with advanced NSCLC who received chemotherapy combined with immunotherapy in 6 different institutions

The ORR of patients treated with docetaxel combined with ramucirumab was significantly better than that of patients with single-agent chemotherapy (55.

Efficacy evaluation

Efficacy evaluation

The median PFS and OS of patients with advanced NSCLC who received second-line treatment were 5.

0 months and 11.

The median PFS and OS of patients with advanced NSCLC who received second-line treatment were 5.

Prognostic analysis

Prognostic analysis

In the docetaxel + ramucirumab regimen group, patients with PFS ≥8.

8 months of chemotherapy combined with immunotherapy (n = 8) had significantly longer PFS in second-line therapy than patients with PFS of chemotherapy combined with immunotherapy <8.

In the docetaxel + ramucirumab regimen group, patients with PFS ≥8.

Finally, the prognostic factors of second-line treatment after chemotherapy combined with immunotherapy in patients with advanced NSCLC were also studied

PFS and OS factor analysis

 PFS and OS factor analysis

In the docetaxel combined with ramucirumab group, the incidence of grade ≥3 neutropenia was 16.

7%

In the docetaxel combined with ramucirumab group, the incidence of grade ≥3 neutropenia was 16.
7%
.
In the single-agent chemotherapy group, the incidence of grade 3 neutropenia was 33.
3%
.
There was no significant difference in the incidence of grade ≥3 hematology (p = 0.
13) and non-hematological toxicity (p = 0.
58) between the docetaxel combined with ramucirumab and the single-agent chemotherapy group
.
There were no treatment-related deaths in either group
.

AEs

AEsAEs

In summary, this retrospective study shows that in the second-line treatment of advanced NSCLC patients, patients with longer progression-free survival who receive chemotherapy combined with immunotherapy are expected to benefit from docetaxel plus ramucirumab treatment
.

In summary, this retrospective study shows that in the second-line treatment of advanced NSCLC patients, patients with longer progression-free survival who receive chemotherapy combined with immunotherapy are expected to benefit from docetaxel plus ramucirumab treatment
.
This retrospective study showed that in the second-line treatment of advanced NSCLC patients, patients with longer progression-free survival who received chemotherapy combined with immunotherapy are expected to benefit from docetaxel plus ramucirumab treatment
.
This retrospective study showed that in the second-line treatment of advanced NSCLC patients, patients with longer progression-free survival who received chemotherapy combined with immunotherapy are expected to benefit from docetaxel plus ramucirumab treatment
.

Original source:

Original source:

Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Takeda T, Takayama K.
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Thorac Cancer.
2021 Nov 17.
doi: 10.
1111/1759-7714.
14236.
Epub ahead of print.
PMID: 34791812.

Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Takeda T, Takayama K.
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Thorac Cancer.
2021 Nov 17.
doi: 10.
1111/1759-7714.
14236.
Epub ahead of print.
PMID: 34791812.
Leave a message here